HemaSphere Journal

This recent paper reports that children w/ T-cell acute lymphoblastic leukemia in the AIEOP-BFM ALL 2009 trial had favorable outcomes Authors highlight that early MRD levels, CNS involvement and prednisone response are important for risk assessment & treatment decisions👉https://f.mtr.cool/prwuxdtqpi

This Editorial highlights how collaboration & mutual support between researchers helped advance understanding of CLL biology, leading to better prognostic tools & therapies Relationships & perseverance are vital in scientific progress, hidden skills not often discussed.👉https://f.mtr.cool/javkjisskd

Our September issue is now complete!   Find the latest #hematology research, always open access 🔓https://f.mtr.cool/rtfwnsvcqm

This study underscores the pronounced elevation of HO-1 levels in pediatric SCD patients, indicating its potential protective role against heme-induced toxicity during childhood. This finding emphasizes the importance of monitoring and managing HO-1 levels in young patients👉https://bit.ly/3IbvCSD

🎙️New Podcast Episode!

Join host HemaSphere Scientific Editor Dr Charles de Bock as he chats with Dr Kai Rejeski. The conversation delves into the complexities of CAR-T therapy, particularly focusing on the associated toxicities & the need for a structured grading system. 👉https://bit.ly/46xKjZA

🐾 Happy World Animal Day (Dierendag)! 🐶🐱🐰🐦🐢

Celebrate the love & joy our furry, feathered, and scaly friends bring into our lives! Our pets help us while we review, edit, write & publish, & at least here at HemaSphere often join Zoom calls. 

📸 Share your cutest pet photos below.  #Dierendag2025.

Gamma delta (γδ) T cells are pivotal in tumor immunosurveillance & are enriched in epithelial tissues This comprehensive review provides an overview of the rationale for γδ T-cell therapy, ongoing clinical trials, challenges & future role of γδ T-cell-based immune therapies👉https://bit.ly/4lpdYYZ

Arsenic trioxide reprograms bone marrow microenvironment to eliminate #MRD in #AML, an old dog learns new tricks.

Read more in our recent issue👉https://f.mtr.cool/syqiavxbqd

These Guidelines on behalf of the European Myeloma Network on VTE prevention & treatment in #MM pts offer evidence-based recommendations. Implementing these guidelines can enhance clinical outcomes and quality of life by reducing morbidity, mortality & treatment interruptions👉https://bit.ly/46kp0uk

Chronic lymphocytic leukemia (CLL) cells reprogram their tumor microenvironment to promote drug resistance and tumor progression. Targeting the AP-1 transcription factor and stromal compartment may offer new treatment strategies.

👉https://f.mtr.cool/ofxyxakidb

Arsenic trioxide reprograms bone marrow microenvironment to eliminate #MRD in #AML, an old dog learns new tricks.

Read more in our recent issue👉https://f.mtr.cool/jvybvprmlv

The novel B-CAP regimen has proven to be a feasible and effective first-line treatment for older patients with advanced-stage classic #HL. It results in high response rates, favorable 3-year PFS, and sustained improvement in health-related QOL.
👉https://f.mtr.cool/uondeedlhy

Authors evaluated real-world outcomes of auto-HCT in 130 adult #NKTCL patients across Asia and Europe. Findings suggest that auto-HCT may be a viable treatment option for selected high-risk patients, especially those in complete remission with undetectable EBV-DNA👉https://f.mtr.cool/icmvhpqdkj

Researchers have identified syntenin as a key regulator in the communication between #BMSC and #MM cells.  Authors in this recent article show that targeting syntenin can disrupt this crosstalk, enhancing the effectiveness of bortezomib therapy & potentially improving outcomes👉https://bit.ly/4fCuhAg

Podcast Replay! 🚨

Dr Adrián Mosquera-Orgueira & Dr Juan Carlos Hernández-Boluda, co-authors of "Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis", discuss the findings & challenges w/  Dr Stephen Hibbs  👉

Looking forward to this exciting meeting and to represent @hemasphere-journal.bsky.social in this session!

HemaTopics are HemaSphere publications focusing on 🔥 hematology topics. This week we focus on the latest HemaTopic by Scientific Editor C de Bock, which discusses the discovery of targeting NPM1 as a new therapeutic target for AML immunotherapy. 

👉https://f.mtr.cool/dlbgueeraz

📰This exciting Review Article highlights the emerging role of inflammation in the pathogenesis of acute myeloid leukemia (AML). Understanding inflammatory processes in AML could guide therapeutic strategies, especially for elderly patients where outcomes remain poor.👉https://bit.ly/3HbJzzt

Authors of this study present the first humanized MPN xenograft model, demonstrating that PV and ET MSCs can sustain both healthy and MPN-associated hematopoiesis. This model offers valuable insights into the interaction between human BM MSCs and JAK2 V617F mutant clones.

👉

We are excited to announce our new #NDLR2026 Meet-the-Editor session, with Editors-in-Chief, Prof Andrew Roberts, @bloodjournals.hematology.org and Prof @jancools.bsky.social, @hemasphere-journal.bsky.social who will share their invaluable insights on #publishing in high-impact #hematology journals.

🎧 Replay! 

Authors of this paper discovered a high-risk subgroup of ped T-LBL, defined by NOTCH1 gene fusions. Prof Roland Kuipers & Dr Jan Loeffen discuss their findings w/ Dr Charles de Bock. 

"NOTCH1 fusions in T‐LBL" is on our website & major podcast platforms https://bit.ly/3NhzIHE

📰
This Editorial,  based on a recent HemaSphere article, https://bit.ly/44Kz3bx , highlights the importance of integrating PD-1 blockade into salvage regimens for patients with #RR cHL who have not had prior PD-1 blockade exposure. 

👉https://bit.ly/44Kz3bx

🔬 Dive into the latest research with @Hemasphere_EHA! Our open access articles provide ground-breaking insights into #hematology. Stay ahead in your field and collaborate with peers. Our latest issue in progress can always be found here 👉 http://bit.ly/3GIlBvj

#Research #OpenAccess

The combination of eprenetapopt and azacitidine shows promise in treating higher-risk myelodysplastic syndromes and oligoblastic #AML with TP53 mutations. The treatment is well-tolerated and demonstrates significant response rates and improved OS.

Read more here👉https://bit.ly/4lrlMu1
#openaccess

🎙️New Episode! 

Dr Charles de Bock hosts Prof Michel Zwaan and Prof Olaf Heidenreich,  two co-authors from the 2025 HemaSphere Award - Top Cited: Biology paper "The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML." 🎧 https://bit.ly/3HJbmr6

The newest issue is open! 

Keep up with the latest hematology research 👉https://bit.ly/3UUm15l

🚨Authors of this study introduce a novel 3D lymph node-like spheroid model for #CLL research. This model better replicates the natural lymph node microenvironment, providing a valuable tool for studying tumor biology and testing therapeutic strategies.

Read it here👉https://bit.ly/46sp7V2

This study on T-cell acute lymphoblastic leukemia (#T-ALL) in infants and toddlers reveals distinct genetic profiles and comparable survival rates to older children. Key findings include significant NKX2 rearrangements and the absence of TLX1/3 dysregulation.

Read more👉https://bit.ly/3SnMjM8

The French National Cancer Institute's Lymphopath network provides expert histopathological reviews for newly diagnosed or suspected lymphomas in France. This study evaluates the impact of the 2017 WHO classification changes on the distribution of noncutaneous #PTCLs in France🏆https://bit.ly/4lH5zkI

📣HemaSphere's August issue is now complete!

This issue is full of 🔥hematology research.  Have a browse📰https://bit.ly/3JHRncU